Recommendation of the President – Leqvio (inlisiran)
On 25 July 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 93/2025on the reimbursement of the medicinal product Leqvio (inlisiran) under the B.101 drug program “Treatment of patients with lipid disorders (ICD-10: E78.0, I21, I22, I25)”